TICKERNERD
Menu
SGRYSGRYHealthcare · Medical Care Facilities

SGRY Stock Forecast: Surgery Partners, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$13
−0.75% on the day

The 12 Wall Street analysts covering Surgery Partners, Inc. hold a median 12-month price target of $19 — +43.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 19 Sept 2026 — in the lower half.

Market cap
$1.7B
Ticker Nerd rank
42 / 100
Median analyst target
$19
Analysts covering
12
Revenue$848.9M+2.7% y/y
Operating income$116.5M
Net income$29.7M
Free cash flow$37.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.9%
1M
−7.0%
YTD
−14.2%
1Y
−39.9%
From 52W high
−42.2%
From 52W low
+15.3%
$11
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SGRY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Surgery Partners, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
68
Accruals
67
Value
65
Revisions
58
Volatility
39
Size
38
Quality
37
Issuance
34
Momentum
27

Growth (68): Sales and profits are climbing, and climbing faster than before.

Momentum (27): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SGRY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SGRY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$12$14$16$18$20$22$24Oct 25Jan 26Apr 26Jul 26SGRYHigh $24Median $19Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
9 Buy3 Hold0 Sell
Low $14Median $19High $24

The green dot is the last close — the median target sits +43.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 6 moved it down.

DateFirmActionRatingTarget
14 Sept 2026JP MorganMaintainsNeutral$14 → $15
11 Aug 2026Cantor FitzgeraldReiteratesOverweight—
11 Aug 2026Cantor FitzgeraldReiteratesOverweight$18
11 Aug 2026RBC CapitalMaintainsOutperform$20 → $19
11 Aug 2026RBC CapitalMaintainsOutperform—
11 Aug 2026TD CowenMaintainsBuy—
11 Aug 2026TD CowenMaintainsBuy$17 → $19
5 Mar 2026MizuhoMaintainsOutperform—
5 Mar 2026MizuhoMaintainsOutperform$19 → $17
5 Mar 2026TD CowenMaintainsBuy—
5 Mar 2026TD CowenMaintainsBuy$28 → $20
5 Mar 2026UBSMaintainsBuy—
5 Mar 2026UBSMaintainsBuy$29 → $21
4 Mar 2026RBC CapitalMaintainsOutperform$31 → $20
4 Mar 2026RBC CapitalMaintainsOutperform—
3 Mar 2026BarclaysMaintainsEqual-Weight$18 → $14
3 Mar 2026BarclaysMaintainsEqual-Weight—
18 Dec 2025MizuhoMaintainsOutperform—
24 Nov 2025JP MorganMaintainsNeutral—
21 Nov 2025BarclaysMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SGRY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SGRY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Surgery Partners, Inc. returned −39.9% against +16.3% for the S&P 500, dividends included.

SGRY vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26SGRYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SGRY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+6.8%
Analysts raising
7
Analysts cutting
1
Fundamentals

Surgery Partners, Inc. (SGRY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2956.0×

Cheaper than 1% of US stocks

Price / sales
0.5×

Cheaper than 81% of US stocks

Price / book
1.0×

Cheaper than 72% of US stocks

EV / EBITDA
11.4×

Cheaper than 33% of US stocks

Growth & margins
Revenue growth (YoY)
2.7%

Higher than 33% of US stocks

Earnings growth (YoY)
2.7%

Higher than 39% of US stocks

Gross margin
22.4%

Higher than 24% of US stocks

Operating margin
13.7%

Higher than 71% of US stocks

Net margin
−2.6%

Higher than 27% of US stocks

Returns & dividend
Return on equity
2.3%

Higher than 48% of US stocks

Return on assets
3.7%

Higher than 69% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Surgery Partners, Inc. (SGRY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Surgery Partners, Inc. has a market value of $1.7B and an enterprise value of $7.4B.

  • Revenue in the twelve months to 30 June 2026: $3.4B. The latest quarter grew 2.7% year on year.

  • Net income over the same four quarters: $81.9M, a 2.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.70.

  • Free cash flow in the twelve months to 30 June 2026: $187.6M.

  • Shares outstanding: 130.9M.

  • Trailing P/E: 2956.0×; forward P/E: 47.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Surgery Partners, Inc. employs 16,000 people — $210K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

SGRY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
SGRYSurgery Partners, Inc.$1.7B
42
ASTHAstrana Health, Inc.$1.7B
63
SNDASonida Senior Living, Inc.$1.8B
28
HCSGHealthcare Services Group, Inc.$1.5B
97
ARDTArdent Health, Inc.$1.5B
56
INNVInnovAge Holding Corp.$1.5B
98
AGLAgilon Health, Inc.$1.5B
66

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Surgery Partners, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SGRY news & analysis

Surgery Partners Completes Sale of Ownership Interests in Idaho Falls Facilities to Intermountain Health; Updates Guidance to Include Impact of the Transaction

GlobeNewsWire · 17 Sept 2026neutral

Surgery Partners announced it has completed the previously announced sale of its ownership interests in its Idaho Falls facilities to Intermountain Health. The company also updated its guidance to include the impact of the transaction.

Why it matters — This transaction and the accompanying guidance update reflect a change in Surgery Partners' asset portfolio and forward-looking financial outlook that investors tracking SGRY would want to account for.

Surgery Partners Director Teresa DeLuca Buys 11,250 Shares

The Motley Fool · 3 Sept 2026positive

Surgery Partners director Teresa DeLuca purchased 11,250 shares valued at approximately $161,000, bringing her total position to 68,093 shares. The buy was reported by The Motley Fool.

Why it matters — An insider purchase by a director can signal confidence in the company's prospects to SGRY watchers.

Likely ETF & Stock Winners From July Jobs Report

Zacks Investment Research · 11 Aug 2026neutral

Zacks Investment Research reported that weak July jobs data has raised hopes for Federal Reserve easing, putting health care and select retail ETFs and stocks in focus.

Why it matters — As a health-care company, Surgery Partners could be among the stocks viewed favorably in a potential Fed easing environment.

Surgery Partners, Inc. (SGRY) Q2 2026 Earnings Call Transcript

Seeking Alpha · 10 Aug 2026neutral

Seeking Alpha published the transcript of Surgery Partners, Inc.'s (SGRY) second-quarter 2026 earnings call. The item provides the full text of management's discussion during the earnings call.

Why it matters — SGRY watchers would refer to this transcript for management's own commentary on the company's second-quarter results and outlook.

Surgery Partners Q2 Earnings Call Highlights

MarketBeat · 10 Aug 2026positive

Surgery Partners reported second-quarter 2026 revenue and adjusted EBITDA that came in above its internal expectations and reaffirmed its full-year outlook. This comes ahead of the anticipated sale of its Idaho Falls market operations to Intermountain Health.

Why it matters — A SGRY watcher would care because the company beat its own internal targets for the quarter and maintained its full-year guidance as it moves forward with the planned divestiture of its Idaho Falls operations.

FAQ

Frequently asked questions about SGRY stock

What is the SGRY stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Surgery Partners, Inc. have a median 12-month price target of $19, with estimates ranging from $14 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SGRY stock a buy right now?

Of the 12 analysts covering Surgery Partners, Inc., 9 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Surgery Partners, Inc. 42 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SGRY?

As at 19 Sept 2026, Surgery Partners, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (68 of 100).

Will SGRY stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +43.4% from the last close, and Ticker Nerd's factor model ranks Surgery Partners, Inc. 42 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SGRY stock forecast for 2030?

No analyst covering Surgery Partners, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGRY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $24 over the next 12 months.

How has SGRY stock performed over the past year?

Surgery Partners, Inc. returned -39.9% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Surgery Partners, Inc. do?

Surgery Partners Inc. is a healthcare services company that owns and operates a broad network of surgical facilities and related care services across the United States.

What is the latest news on SGRY?

The most recent item we track (GlobeNewsWire, 17 Sept 2026): "Surgery Partners Completes Sale of Ownership Interests in Idaho Falls Facilities to Intermountain Health; Updates Guidance to Include Impact of the Transaction". Surgery Partners announced it has completed the previously announced sale of its ownership interests in its Idaho Falls facilities to Intermountain Health. The company also updated its guidance to include the impact of the transaction.

Company

About Surgery Partners, Inc.

Surgery Partners Inc. is a healthcare services company that owns and operates a broad network of surgical facilities and related care services across the United States. The company focuses on outpatient and short-stay procedures delivered through ambulatory surgery centers and surgical hospitals, serving patients in specialties such as orthopedics, pain management, ophthalmology, gastroenterology, and general surgery. Its integrated model also includes anesthesia services, multi-specialty physician practices, diagnostic testing, urgent care facilities, and other ancillary services that support clinical operations. Surgery Partners Inc. plays a significant role in the outpatient care market by connecting providers, facilities, and supporting services within a coordinated healthcare delivery platform. Headquartered in Brentwood, Tennessee, the company serves a wide range of communities through locations in multiple states.

CEO Mr. J. Eric Evans · 16,000 employees · United States · https://www.surgerypartners.com